- The stock price of Moderna Inc (NASDAQ: MRNA) increased by over 5% pre-market today. This is why it happened.
The stock price of Moderna Inc (NASDAQ: MRNA) increased by over 5% pre-market today. Investors appear to be responding positively to a report that the COVID-19 vaccines made by Pfizer and Moderna that use mRNA technology provide the biggest boost for antibody levels when given 10-12 weeks after the second dose, according to a British study via Reuters.
The COV-Boost study was cited by British government officials while announcing that Pfizer and Moderna were preferred for use in the country’s booster. The data was made publicly available today.
This study also founded that 6 of the 7 boosters examined had enhanced immunity following the initial vaccination with the Pfizer-BioNTech vaccine while all 7 increased immunity when given after 2 doses of the AstraZeneca vaccine.
“A third dose will be effective for many of the vaccines we’ve tested and in many different combinations,” said Professor Saul Faust in a statement via Reuters — who works as an immunologist at the University of Southampton and the lead of the trial lead.
The COV-Boost study had pre-dated the spread of the Omicron variant. But the study found that booster shots helped generate a broad T-cell response against the Beta and Delta variants.
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.